Biologix announced that it has received BRL 6 million in a round of funding led by new investor Kortex Ventures on May 7, 2024. The transaction included participation from new investors Fleury S.A., Laboratório Sabin de Análises Clínicas S.A., Bradesco Seguros S.A., Financial Investment Arm, and returning investor Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.2 BRL | -0.35% | -1.53% | -21.29% |
05-10 | Fleury Seeks Acquisitions | CI |
05-10 | Transcript : Fleury S.A., Q1 2024 Earnings Call, May 10, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.29% | 1.45B | |
-19.54% | 8.05B | |
+68.16% | 4.32B | |
+6.69% | 2.74B | |
-2.98% | 2.6B | |
-50.95% | 1.97B | |
-18.54% | 1.68B | |
+16.69% | 1.2B | |
-44.86% | 1.12B | |
+17.43% | 975M |
- Stock Market
- Equities
- FLRY3 Stock
- News Fleury S.A.
- Biologix announced that it has received BRL 6 million in funding from Kortex Ventures, Fleury S.A., Laboratório Sabin de Análises Clínicas S.A., Bradesco Seguros S.A., Financial Investment Arm, Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein